# Amneal Pharmaceuticals Inc. (AMRX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $17.44, market value $6.1 billion.

## Valuation
- **P/E (trailing): 36.3×** (5-yr avg 62.9×, 3-yr avg 57.3×). Amneal Pharmaceuticals Inc. trades at 36.3× trailing earnings, well below its own five-year average of 62.9×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 15.0×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.10**. A PEG of 0.10 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.9×**. Each dollar of revenue is priced at 1.9×.
- **Price / book: 169.3×**. The shares trade at 169.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 2.1%** (5-yr avg 15.5%). Free cash flow equals 2.1% of the market value, below its five-year average of 15.5%, so the shares are pricier on cash than usual.
- **Earnings yield: 2.8%**. The inverse of the P/E: 2.8% of the price is earned each year.

## Profitability
- **Gross margin: 39.3%**. Amneal Pharmaceuticals Inc. keeps 39.3% of revenue after the direct cost of what it sells.
- **Operating margin: 14.6%**. 14.6% of revenue is left after running the business.
- **Net margin: 2.4%**. 2.4% of each dollar of sales reaches the bottom line.
- **Return on equity: -101.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 16.2%**. Return on all capital, debt included, is 16.2%: comfortably above what that capital costs.
- **Return on assets: 4.3%**. Each dollar of assets produces 4.3% of profit.

## Growth
- **Revenue growth (1 yr): 8.0%** (3-yr 10.9%/yr, 5-yr 8.7%/yr). Revenue grew 8.0% over the last year, against 8.7% a year compounded over five years.
- **EPS growth (1 yr): 157.9%** (5-yr -18.5%/yr). Earnings per share rose 157.9%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 143.5%/yr**. Free cash flow has compounded at 143.5% a year over three years.

## Financial health
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Amneal Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (5 analysts). 5 analysts cover Amneal Pharmaceuticals Inc.; the consensus is buy, with an average price target of $21.00 (+20% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 82.6%** (YTD 38.4%, 3-mo 26.8%). The shares are up 82.6% over twelve months including dividends.
- **From 52-week high: -9.4%** (83.8% above the low). Trading 9% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 45**. An RSI of 45 is neutral.
- **Beta (1 yr): 0.62** (volatility 34%). Beta of 0.62 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AMRX · Page: https://foliofundamentals.com/stocks/amrx

Not investment advice.